Literature DB >> 1906179

Expression of von Willebrand factor "Normandy": an autosomal mutation that mimics hemophilia A.

E A Tuley1, C Gaucher, S Jorieux, N K Worrall, J E Sadler, C Mazurier.   

Abstract

von Willebrand disease Normandy (vWD Normandy) is a recently described phenotype in which a mutant von Willebrand factor (vWF) appears structurally and functionally normal except that it does not bind to blood coagulation factor VIII. This interaction is required for normal survival of factor VIII in the circulation; consequently, vWD Normandy can present as apparent hemophilia A but with autosomal recessive rather than X chromosome-linked inheritance. A vWF missense mutation, Thr28----Met, was identified in the propositus in or near the factor VIII binding site. The corresponding mutant recombinant vWF(T28M) formed normal multimers and had normal ristocetin cofactor activity. However, vWF(T28M) exhibited the same defect in factor VIII binding as natural vWF Normandy, confirming that this mutation causes the vWD Normandy phenotype. The distinction between hemophilia A and vWD Normandy is clinically important and should be considered in families affected by apparent mild hemophilia A that fail to show strict X chromosome-linked inheritance and, particularly, in potential female carriers with low factor VIII levels attributed to extreme lyonization.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1906179      PMCID: PMC52086          DOI: 10.1073/pnas.88.14.6377

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

Review 1.  Cell biology of von Willebrand factor.

Authors:  D D Wagner
Journal:  Annu Rev Cell Biol       Date:  1990

2.  The functional domains of coagulation factor VIII:C.

Authors:  R L Burke; C Pachl; M Quiroga; S Rosenberg; N Haigwood; O Nordfang; M Ezban
Journal:  J Biol Chem       Date:  1986-09-25       Impact factor: 5.157

3.  A monoclonal antibody to von Willebrand factor (vWF) inhibits factor VIII binding. Localization of its antigenic determinant to a nonadecapeptide at the amino terminus of the mature vWF polypeptide.

Authors:  W F Bahou; D Ginsburg; R Sikkink; R Litwiller; D N Fass
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

4.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

5.  Localization of a factor VIII binding domain on a 34 kilodalton fragment of the N-terminal portion of von Willebrand factor.

Authors:  Y Takahashi; M Kalafatis; J P Girma; K Sewerin; L O Andersson; D Meyer
Journal:  Blood       Date:  1987-11       Impact factor: 22.113

6.  A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor.

Authors:  P A Foster; C A Fulcher; T Marti; K Titani; T S Zimmerman
Journal:  J Biol Chem       Date:  1987-06-25       Impact factor: 5.157

7.  Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions.

Authors:  G Urlaub; P J Mitchell; E Kas; L A Chasin; V L Funanage; T T Myoda; J Hamlin
Journal:  Somat Cell Mol Genet       Date:  1986-11

8.  Localization within the 106 N-terminal amino acids of von Willebrand factor (vWF) of the epitope corresponding to a monoclonal antibody which inhibits vWF binding to factor VIII.

Authors:  G Piétu; A S Ribba; P Meulien; D Meyer
Journal:  Biochem Biophys Res Commun       Date:  1989-08-30       Impact factor: 3.575

9.  Human von Willebrand factor: a multivalent protein composed of identical subunits.

Authors:  M W Chopek; J P Girma; K Fujikawa; E W Davie; K Titani
Journal:  Biochemistry       Date:  1986-06-03       Impact factor: 3.162

10.  Incorporation of a charged amino acid into the membrane-spanning domain blocks cell surface transport but not membrane anchoring of a viral glycoprotein.

Authors:  G A Adams; J K Rose
Journal:  Mol Cell Biol       Date:  1985-06       Impact factor: 4.272

View more
  14 in total

1.  A common ancestor more than 10,000 years old for patients with R854Q-related type 2N von Willebrand's disease in Italy.

Authors:  Alessandra Casonato; Viviana Daidone; Giovanni Barbon; Elena Pontara; Irene Di Pasquale; Lisa Gallinaro; Letizia Marullo; Giorgio Bertorelle
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

2.  Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations.

Authors:  B Boylan; A S Rice; C De Staercke; M E Eyster; H M Yaish; C M Knoll; C J Bean; C H Miller
Journal:  J Thromb Haemost       Date:  2015-05-09       Impact factor: 5.824

Review 3.  Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

Authors:  Steven W Pipe; Robert R Montgomery; Kathleen P Pratt; Peter J Lenting; David Lillicrap
Journal:  Blood       Date:  2016-09-01       Impact factor: 22.113

4.  Defective dimerization of von Willebrand factor subunits due to a Cys-> Arg mutation in type IID von Willebrand disease.

Authors:  R Schneppenheim; J Brassard; S Krey; U Budde; T J Kunicki; L Holmberg; J Ware; Z M Ruggeri
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

Review 5.  Von Willebrand's disease.

Authors:  I M Nilsson; S Lethagen
Journal:  Indian J Pediatr       Date:  1993 Mar-Apr       Impact factor: 1.967

6.  Phylogenetic and functional analysis of histidine residues essential for pH-dependent multimerization of von Willebrand factor.

Authors:  Luke T Dang; Angie R Purvis; Ren-Huai Huang; Lisa A Westfield; J Evan Sadler
Journal:  J Biol Chem       Date:  2011-05-17       Impact factor: 5.157

7.  Accelerated clearance alone explains ultra-large multimers in von Willebrand disease Vicenza.

Authors:  A Gézsi; U Budde; I Deák; E Nagy; A Mohl; A Schlammadinger; Z Boda; T Masszi; J E Sadler; I Bodó
Journal:  J Thromb Haemost       Date:  2010-01-17       Impact factor: 5.824

8.  Multi-step binding of ADAMTS-13 to von Willebrand factor.

Authors:  H B Feys; P J Anderson; K Vanhoorelbeke; E M Majerus; J E Sadler
Journal:  J Thromb Haemost       Date:  2009-09-18       Impact factor: 5.824

9.  von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib.

Authors:  I Rabinowitz; E A Tuley; D J Mancuso; A M Randi; B G Firkin; M A Howard; J E Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

10.  Human mutational constraint as a tool to understand biology of rare and emerging bone marrow failure syndromes.

Authors:  Joseph H Oved; Daria V Babushok; Michele P Lambert; Nicole Wolfset; M Anna Kowalska; Mortimer Poncz; Konrad J Karczewski; Timothy S Olson
Journal:  Blood Adv       Date:  2020-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.